ORIGIN
The transgene was constructed by inserting four copies of the chicken chromatin insulator sequence into the multiple cloning region of the pHelix1. An expression cassette fragment consisting of the neuron-specific enolase (NSE) promoter, a random filler sequence, and the SV40 polyadenylation signal sequence was then subcloned into a blunted Bam H1site on the pHelix/CI vector such that it was flanked on each side by two copies of the chromatin insulators. The G100L MMP-9 cDNA was subcloned as a Xba1fragment into the NHe1 and SPe1sites of the vector, replacing some of the random filler sequence. The transgene was purified using Elutip columns and used for pronuclear injection into FVB/N embryos, which were then transferred to pseudopregnant CD-1 females. Founder transgenics were identified by PCR using tail tissue. Founder mice were bred to FVB/N mates and transgene-positive offspring were used to maintain the individual transgenic lines. Transferred to Charles River under exclusive license in 2011.
STRAIN CODE
Coming Soon
COAT COLOR
White
MUTATION INFORMATION
Matrix Metalloproteinases (MMPs) are expressed and secreted from cells as inactive zymogens, the latency of which are maintained through a cysteine switch mechanism in the highly conserved region of the propeptide. Due to the tight regulation of enzyme activity, through a two-step process, transgenic animals overexpressing MMP-9 may give rise to increased expression of the latent enzyme, but not the active enzyme. By designing mutant forms of the enzyme that autocatalytically removed the prodomain to yield active enzyme, the effects of MMP-9 in the CNS can be studied. Multiple mutations were made by site-directed mutagenesis and several mutations disrupted the function of the cysteine switch mechanism, leading to dysregulation of MMP-9.
RESEARCH APPLICATION
Inflammation, extracellular remodeling
ORDERING INFORMATION
Please call 1.800.LAB.RATS if you would like to place an order.
For additional information about MMP9 mice, please contact Technical Services at 1.877.CRIVER.1 (1.877.274.8371) or askcharlesriver@crl.com.
DISCLAIMER
MMP9 mice may be subject to the licensed patents and are sold only for research purposes under agreement from Pfizer, Inc.